Prion-Disease Trials on the Horizon?

The discoverer of prions, the pathogens implicated in the fatal, brain-wasting mad cow disease (bovine spongiform encephalopathy, BSE) and Creutzfeldt-Jakob disease (CJD), announced recently that a therapy against them would likely be available within the next five to 10 years, but he added that scientists are still mystified by exactly what circumstances cause the pathogens to produce infections in animals and humans. "We thought that the number of cases of the disease would increase two to th

Written byJennifer Fisher Wilson
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

"We thought that the number of cases of the disease would increase two to three times, but the number of cases in 2001 was similar to the number in 2000," Stanley B. Prusiner, 1997 Nobel Prize winner, told a crowded room of scientists at the University of Pennsylvania on Feb. 13. Prion diseases are difficult to predict, he said, because they involve so many variables. For example, it is still unknown why the new variant form of CJD disease, caused by BSE, is confined to young people while inherited CJD, also known as sporadic CJD, afflicts only the aged, he said.

All the same, after almost 20 years researching prions, "I think we now know enough about these diseases to really mount a program that hopefully will give us a therapy," said the neurologist and biochemist who directs the University of California, San Francisco, Institute for Neurodegenerative Diseases. The most ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies